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htcense.Abstract Objective: The objective of our study was to assess the impact of thrombocytopenia on
percutaneous radiofrequency ablation (RFA) therapy of Hepatocellular carcinoma (HCC) in
patients with liver cirrhosis.
Material and methods: We analyzed retrospectively 64 patients with liver cirrhosis and thrombocy-
topenia, deﬁned as a platelet count of less than 100 · 103/mm3 that had undergone percutaneous
RFA to treat 86 HCCs. The Kaplan–Meier and Cox regression methods were used to predict hem-
orrhage, and time to the ﬁrst decompensation event, deﬁned as the development of ascites, hepatic
encephalopathy, variceal hemorrhage, and deterioration of liver function to Child-Pugh class B/C.
Results: There were no signiﬁcant risk factors of hemorrhage. Univariate and multivariate analyses
revealed that liver decompensation was clearly linked to prothrombin activity (p= 0.010 and
p= 0.006, respectively) and a 6 63% of prothrombin activity was found as signiﬁcant threshold
for the occurrence of liver decompensation (p= 0.003) conﬁrmed by the Cox model (p= 0.05).
Conclusion: Percutaneous RFA for HCC can be performed safely without the need for support, in
patients with liver cirrhosis and thrombocytopenia up to 37 · 103/mm3.
 2013 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
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Hepatocellular carcinoma (HCC) is now treated with invasive
therapies, such as resection and, minimally invasive therapies
as radiofrequency ablation (RFA) (1). In either case, thrombo-
cytopenia as the most essential abnormality in hypersplenism
with liver cirrhosis seems to adversely affect patient’s tolerance
of these HCC treatments (2).
RFA has been accepted as a safe and effective technique,
for the treatment of an unresectable HCC. An advantage of
the use of RFA includes low mortality (0–0.5%), morbidity,Production and hosting by Elsevier B.V.
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P = 0.006 by Log Rank (Mantel-Cox) test
Fig. 1 Kaplan–Meier survival curves by risk score: the difference in survival between these two risk groups was signiﬁcant (P= 006).
The estimated prothrombin group > 63% (38 patients) and prothrombin group 6 63 (26 patients) survival rates were 97.4% (95%
conﬁdence interval: 16–18) and 73.1% (95% conﬁdence interval: 13–77), respectively.
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has largely replaced surgical resection for the treatment of pa-
tients with small (<3 cm) HCCs, and poor hepatic reserve, be-
cause of underlying liver cirrhosis (3).
However, the real incidence of thrombocytopenia-related
limitation for RFA of HCC treatment is unclear. In several
institutions, HCC patients with severe thrombocytopenia re-
ceived platelet transfusion or splenectomy to improve their
thrombocytopenic status. These measurements may be avail-
able in some institutions than that in other general institutions
especially that have no designated oncology center specializing
in HCC (4).
In Egypt, we have a relatively high proportion of severe end
stage patients desiring intensive care, and a small number of
specialized hospitals in the treatment of HCC. Although sple-
nectomy and arterial splenic embolization are efﬁcient meth-
ods for treating HCC patients with severe thrombocytopenia,
these treatment options are not always available for patients
with advanced cirrhosis. Thus, severe thrombocytopenia is still
a major unresolved issue affecting HCC treatment, and
eltrombopag, a thrombopoietin-receptor agonist, is expected
to improve HCC treatment (2).
The absolute value of the platelet count in liver cirrhosis
may not be crucial in determining the risk of bleeding, as it
is well recognized that even those patients with normal pro-
thrombin times and platelet counts can have severely deranged
bleeding times (5). Nevertheless, for a percutaneous RFA of
HCC in the patient with liver cirrhosis, the platelet count
was felt to be safe without the need for support, in need for
identiﬁcation.
The effect on bleeding of thrombocytopenia due to
hypersplenism resulting from liver cirrhosis following
RFA of HCC has, to our knowledge, not been studied
in detail.
The purpose of this study was to assess whether percuta-
neous RFA for HCC is a safe procedure in patients with li-
ver cirrhosis and thrombocytopenia, and try to reach the
minimum platelet count felt to be safe without the need
for support.2. Patients and methods
2.1. Study design
In accordance with a protocol approval by our institutional re-
view board, radiology reports, laboratory and medical records
were retrospectively reviewed in all patients with HCCs, who
initially managed by percutaneous RFA. From June 2008
through September 2011, among HCCs, 256 patients were
treated with RFA in our center, we identiﬁed 64 with cirrhosis
and thrombocytopenia as reﬂected by a platelet count of 37–
99 · 103/mm3. Statistical analysis was performed for factors
suggested to contribute to bleeding or liver decompensation.
2.2. Selection criteria for RFA procedures
In our department, the decision of treatment is individualized
for each patient by a medico-surgical staff after staging the dis-
ease. Selection criteria for RFA of the HCC were (i) tumor size
less than 5 cm in diameter, (ii) no portal or segmental invasion
adjacent to the tumor, (iii) less than four concomitant tumors
in the whole liver, and (iv) contraindications to resection as
ﬁrst-line treatment. Patients were not eligible for RF treatment
in cases of extra hepatic metastasis, severe liver dysfunction
(Child-Pugh class C), or signiﬁcantly abnormal coagulation
test results with prothrombin activity < 40% and platelet
count < 30 · 103/mm3.
2.3. Pretreatment work-up
Pre-treatment work-up included gray-scale and color Doppler
ultrasound (US) examination, by using 3.5-MHz probes with
(SONOLINE G20 Ultrasound, Germany), as well as non en-
hanced and dual-phase contrast material–enhanced computed
tomography (CT) using Multislice CT unit, a GE Light Speed
Ultra (General Electric Healthcare, Milwaukee). The ﬁrst non-
enhanced scanning over the entire liver with 8-mm collimation,
a pitch of 1.5, and reconstructions every 8 mm was followed by
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a pitch of 1.5, and reconstructions every 5 mm for 20 s during
the arterial phase and for 60 s during the portal venous phase
of the intravenous injection of iodinated contrast medium. A
170-mL volume of the contrast medium (iohexol, Omnipaque
[300 mg of iodine per milliliter]; Amersham, Cork, Ireland)
was systematically injected, at a rate of 5 mL/min, through
an 18-gauge catheter inserted into a forearm vein.
All patients underwent the following laboratory tests before
RFA: Complete blood count, serum aspartate aminotransfer-
ase, serum alanine aminotransferase, serum total bilirubin, ser-
um albumin, blood urea nitrogen, serum creatinine,
prothrombin time, hepatitis B surface antigen and hepatitis
C antibody, and serum levels of alpha-fetoprotein. All labora-
tory tests were performed within 48 h before RFA procedure.
2.4. RFA procedure
RFA was performed with a percutaneous approach by using
3.5-MHz probes for real-time US guidance with (SONOLINE
G20 Ultrasound, Germany). All procedures were performed in
the operative suite under strictly aseptic conditions, by one
author, who had 7 years of experience in performing US-
guided interventional procedures. As the safety and efﬁcacy
of the procedure depended on the patient being absolutely still
during puncture and treatment, general anesthesia with tra-
cheal intubation and assisted ventilation was used. The anes-
thetic protocol was 0.1–2 lg/kg intravenous injections of
sufentanil (Sufenta; Janssen-Cilag, Issy-les-Moulineaux,
France), 1.5–2.5 mg/kg of propofol (Diprivan; AstraZeneca,
Rueil-Malmaison, France). For percutaneous RFA, patients
were treated using the RITA 1500 generator (RITA Medical
Systems Inc., Mountain View, CA, USA). This system consists
of a generator that supplied up to 150 W of power and a mul-
titined expandable electrode (StarBurst XL, RITA). The mul-
titined expandable electrode consisted of a 15-gauge insulated
cannula, 15–25 cm in length that contains nine individual elec-
trode tines deployed in situ after ultrasound-guided placement
of the needle electrode into the liver tumor. Depending on tu-
mor size, shape, and location, a deﬁned treatment strategy was
adopted that consisted of a mathematical protocol, an individ-
ualized protocol, and adjunctive measures. The strategy to
achieve complete necrosis of the tumor was to ablate a periph-
eral margin of 0.5–1 cm of normal hepatic tissue surrounding
the tumor as well as the entire tumor itself so; multiple over-
lapping ablation techniques were used whenever necessary
according to the volume of the tumor and to the spread of
hyperechogenic area induced by RF energy deposition during
the procedure.
2.5. Post treatment assessment and follow-up
All patients were outpatients before the procedure, and admit-
ted two hours before the procedure. After RFA, the patients
underwent close medical observation, 1–2 h to detect any
bleeding in the liver or the peritoneal cavity. All patients stayed
in the hospital overnight, and any adverse event was evaluated
and recorded. Patients were discharged from the hospital, and
were followed at the outpatient clinic with physical examina-
tion and laboratory tests at one week, one month, and then
three-month intervals thereafter. All follow-up images in-cluded CT imaging of the abdomen before and after the intra-
venous administration of contrast. Response to treatment was
assessed one month after ablation by the same CT scan tech-
nique previously described. The ablation was considered as
complete on the basis of all of the following ﬁndings: (a) no
contrast enhancement was detected within or around the tu-
mor, (b) the margins of the ablation zone were clear and
smooth, and (c) the ablation zone extended beyond the tumor
borders (14). Follow-up of patients was updated consulting a
prospective data base.
2.6. Study endpoints and deﬁnitions
Complications were deﬁned as immediate (624 h after the pro-
cedure), periprocedural (within 30 days), delayed (after
30 days) and minor or major according to the recommenda-
tions of The Working Group on Image-Guided Tumor Abla-
tion (6). Bleeding complications were classiﬁed as major (any
hemodynamically signiﬁcant or life-threatening hemorrhage)
or minor (superﬁcial hematoma, either visible or palpable, or
superﬁcial oozing from the puncture site but without hemody-
namic consequence). Because the natural courses of cirrhosis
direct usually toward the liver decompensation, we selected
the end point 30 days within the start time of the procedure,
during which the appearance of at least one episode of ascites,
jaundice, encephalopathy, or variceal bleeding was considered
to be related to RFA (6). More than 30 days after ablation,
other events might further compromise the liver functional re-
serve and confound the results. A per ablative death was de-
ﬁned as death in hospital or within 30 days in the case of
patients discharged from hospital (6).
The observation end point for tumor progression was either,
(1) local, deﬁned as re-appearance of any focal or nodular
peripheral enhancement in the ablated lesion, or (2) distal which
was recognized when new nodules at other sites of the liver
showing contrast enhancement during CT-arterial phase (7).
2.7. Statistical analysis
The risk factors for bleeding or liver decompensation after
RFA included (i) patient factors such as age, gender, Child-
Pugh classiﬁcation, etiology of cirrhosis, blood platelet count,
and prothrombin time; (ii) tumor factors such as, maximum
tumor size and number of tumor nodules, and (iii) RF techni-
cal factors such as type of electrode. The variables found sig-
niﬁcant by univariate analysis were further analyzed by
multivariate analysis using the Cox proportional hazard
regression model. All P values were two-sided and the signiﬁ-
cant level was <0.5.
3. Results
3.1. Treatment outcome
RFA was successful in 57 (89.1%) patients and 7 (10.9%) pa-
tients had residual unablated tumor in the ablation zone. Four
patients underwent a successful second RFA procedure (with
the same RFA device) and the remaining three patients could
not complete the treatment because one patient had extra he-
patic metastasis, and the other two patients developed severe
hepatic decompensation. The post-treatment follow-up varied
Table 2 Overview of complications including bleeding and
liver decompensation.
Types of complications Frequency Bleeding Liver
decompensation
21 2 8
Immediate complication 2 1 1
Encephalopathy 1 – 1
*Hematoma and right
pleural eﬀusion
1 1 –
Peri procedural
complication
14 1 7
Spleen infarction 3 – –
Septicemia 1 – –
Ascites 4 – 4
Sub capsular hematoma 1 1 –
*Ascites and portal
thrombosis
1 – 1
Portal vein thrombosis 1 – –
Right pleural eﬀusion 1 – –
Variceal bleeding 2 – 2
Delayed complication 5 0 0
Ascites – – –
Hepatic aneurysm 1 – –
Biliary stricture 3 – –
Arterio-portal ﬁstula 1 – –
* One patient developed immediate and periprocedural
complication.
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follow-up, local tumor progression developed in nine patients
(14.1%), distant tumor progression observed in 6 (9.4%) pa-
tients, and both local and distant tumor progressions devel-
oped in 7 (9.94%) patients.
3.2. Complications
No patients were excluded from analysis owing to ablation
mortality or being lost to follow-up. Each category of risk fac-
tors related to patient demo-graphics, lesions, and the elec-
trode are shown in Table 1, and overall complications
including bleeding and liver failure are shown in Table 2. Hem-
orrhage occurred in 2 of 64 patients (3.1%). The cause of hem-
orrhage in both patients was sub capsular hematoma that was
discovered by an US examination after the disabling pain per-
sisted more than 3 days after the RFA procedure. The ﬁrst pa-
tient (1.6%), was Child Pugh A, and had a 3.3-cm subcapsular
HCC located in segment 3. After RFA procedure a 1–3 cm
hematoma in front of the ablation zone developed and re-
solved conservatively within 4 weeks. The second patient,
was Child-Pugh B, and had two HCCs measuring 2 cm and
4 cm and located at segments 7 and 3, respectively. The hema-
toma was 2 · 3 cm and resolved spontaneously within 4 weeks.
No need for blood transfusion or drainage of both patients.
Univariate analysis revealed no signiﬁcant variable contrib-
utor to the risk of hemorrhage. There was a tendency for hem-
orrhage with Child-Pugh class; the incidence of hemorrhage
for Child-Pugh A, was 1.8% (1 of 57); the incidence for
Child-Pugh B was 14.3% (1 of 7), but the difference was not
statistically signiﬁcant (v2 test; p= 0.072). Platelet count and
prothrombin activity did not signiﬁcantly affect the occurrence
of hemorrhage (p= 0.819, and p= 0.348, respectively).
Hepatic decompensation deﬁned as development of
ascites, hepatic encephalopathy, variceal hemorrhage, andTable 1 Patient characteristics (n= 64).
Category Mean (range) (%)
Age (y) 62 (35–83)
Male sex 49 (76%)
Platelet count 76 (37–99) · 103/mm3
Prothrombin activity (%) 66 (42–100)
Etiology of cirrhosis
HCV 35 (54.7%)
HBV 3 (4.7%)
B/C 2(3.1%)
Alcohol 21 (32.8%)
Metabolic 3 (4.7%)
Child-Pugh class
A 57 (89.1%)
B 7 (10.9%)
Number of tumor nodules
1 47 (73.4%)
2 13 (20.3%)
3 3 (4.7)
4 1 (1.6%)
Mean tumor size (mm) 26 (10–60)
Note––Values in parentheses are percentages (%), or range.deterioration of liver function to Child-Pugh class B/C, devel-
oped in 8 of 64 patients (12.5%) along the course of follow-up.
We recorded a case of encephalopathy developed immediately
(1.6%), this case had 4 HCCs totally measuring 6 cm, and the
remaining seven (10.9%) patients had it periprocedural; two
patients had variceal bleeding and ﬁve patients had ascites.
All ascites were mild to moderate, and there was no need for
intervention.
Table 3, shows the existence of clearly signiﬁcant links,
between liver decompensation and the prothrombin activity
(%) (p= 0.017). Other factors such as, age, sex, etiology of
cirrhosis, Child-Pugh class, blood platelet count, maximum
tumor size, number of tumor nodules and type of electrode
did not have a relationship with liver decompensation.
3.3. Analysis of interaction between signiﬁcant variables
Factors found signiﬁcant in contributing to risk of liver
decompensation after univariate analysis were evaluated for
possible association and interaction. Signiﬁcance attached to
prothrombin, (p= 0.006) was conﬁrmed, taking into account
strengthens its intensity. The use of a regression tree made us
able to put a signiﬁcant threshold: prothrombin = 63%;
p= 0.003. The simultaneous introduction in a Cox model re-
vealed that in a more limiting way the calculated threshold of
prothrombin (p= 0.053), was a predictive factor for liver
decompensation. In Figure 1, Kaplan–Meier survival curves
by risk score revealed signiﬁcant difference in survival between
these two risk groups. The estimated prothrombin
group > 63% (38 patients) and prothrombin group 6 63 (26
patients) survival rates were 97.4% (95% conﬁdence interval:
Table 3 Relationship between variables and bleeding/hepatic decompensation in 64 sessions of RFA therapy according to univariate
and Cox regression.
Bleeding P value Liver decompensation P value
No (n= 62) Yes (n= 2) No (n= 56) Yes (n= 8)
Sex 0.368 0.911
Male 48 (98) 1 (2) 43 (87.8) 6 (12.2)
Female 14 (93.3) 1 (6.7) 13 (86.7) 2 (13.3)
Age 0.319 0.533
Platelet 0.819 -0.015
Prothrombin activity 0.348
Prothrombin <= 63 26 (40.6) 7 (87.5) 0.017
Prothrombin > 63 38 (59.4) 1 (12.5) 0.053*
Etiology of cirrhosis 0.376 0.314
HCV 35(100) 0(0) 32(91.4) 3(8.6)
HBV 3 (100) 0(0) 3 (100) 0(0)
B/C 2(100) 0(0) 1(50) 1(50)
Bilharzial 19(90.5) 2(9.5) 17(81) 4(19)
Metabolic 3(100) 0(0) 3(100) 0(0)
Child-Pugh class 0.072 0.173
A 56 (98.2) 1 (1.8) 51 (89.5) 6 (10.5)
B 6 (85.7) 1 (14.3) 5 (71.4) 2 (28.6)
Mean tumor size (mm) 0.165 0.414
Number of tumor 0.758 0.657
nodules
1 46 (97.9) 1 (2.1) 41 (87.2) 6 (12.8)
2 12 (92.3) 1 (7.7) 12 (92.3) 1 (7.7)
3 3 (100) 0(0) 2 (66.7) 1 (33.3)
4 1 (100) 0(0) 1 (100) 0 (0)
Type of electrode 0.637 0.408
Monopolar radionics 15 (93.8) 1 (6.3) 16 (100) 0 (0)
Monopolar cluster 14 (100) 0 (0) 12 (85.7) 2 (14.3)
Monopolar berchtold 12 (92.3) 1 (7.7) 11 (84.6) 2 (15.4)
Bipolar berchtold 19 (100) 0 (0) 15 (78.9) 4 (21.1)
Bipolar celon 2 (100) 0(0) 2 (100) 0 (0)
Note. Numbers in parentheses are percentages.
* Cox model test for trend of: 1-Prothrombin activity 663 vs. >63.
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respectively.
4. Discussion
In the present study, the platelet count felt to be safe without
the need for support during RFA therapy for HCC was
37 · 103/mm3. For a percutaneous liver biopsy the minimum
platelet count felt to be safe without the need for support is
60 · 103/mm3 (5).
A number of investigators have shown that the degree of
bleeding from the liver puncture site bears no correlation to
peripheral blood coagulation parameters, and hemorrhage
may result from laceration of the liver caused by deep inspira-
tion or patient movement during biopsy, or result from the
penetration of distended vein, aberrant arteries or branch of
the hepatic artery or portal vein (8).
It should, however, be borne in mind that during a percu-
taneous RFA of HCC, the liver is not the only structure tobe punctured and the skin and subcutaneous tissues (and occa-
sionally other organs) can bleed. Thus, peripheral indices of
clotting must still be taken into consideration. During percuta-
neous liver biopsy, some of the investigators have postulated
that this discrepancy in liver bleeding time may be due to the
inherent elasticity of the biopsy track collapsing down after
the core has been taken, together with the high local concen-
trations of clotting factors within the hepatic parenchyma (8).
During RFA therapy of HCC, a lower rate of hemorrhage
is observed although the needle electrodes of large diameter
(17–14 gauge) are used due to, traversing sufﬁcient normal he-
patic parenchyma as well as cauterization of the needle tract
after ablation. In addition to, the operator’s skill in placing
the RF needle electrode safely without traversing major vessels
and in minimizing the amount of needle repositioning (9).
Also, as long as there is difference in efﬁciency of practice,
the operators of RFA should have a lower rate of hemorrhage.
Several large studies suggested that about 90% of the bleeds
occurred in patients with an INR< 1.3 and reinforce the fact
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ance that the patient will not bleed after the procedure of liver
biopsy (8). Our study agreed with these studies and revealed no
increased risk of bleeding associated with prothrombin activity
up to 42%.
Although worsening of liver function in patients with cir-
rhosis is less common following RFA for HCC in comparison
with surgical resection, the incidence of such adverse effect
after RFA has been reported in a range from 0.14% to 0.6%
in multicenter studies (10). Eight patients (8/64, 12.5%) of liver
decompensation were observed in our study, one patient (1/64,
1.6%) had encephalopathy and seven patients (7/64, 10.9%)
suffered from transient ascites. The reported high overall per-
centage of liver decompensation can be explained ﬁrstly be-
cause in the literature transient ascites are not always
regarded as liver decompensation related to RFA (11), sec-
ondly the number of Child-Pugh B patients (10.9%) included
in our study was especially high, and thirdly in contrast to pre-
vious studies reporting lower incidence of liver decompensa-
tion after RFA, all patients in our series had cirrhosis and
thrombocytopenia. It is known that patients with cirrhosis
and thrombocytopenia related to portal hypertension, have
an increasing risk of liver decompensation especially after sur-
gical resection (2). An analysis of 1222 patients, who under-
went hepatectomy, demonstrated that thrombocytopenia was
a signiﬁcant risk factor for postoperative morbidity and hospi-
tal mortality (12).
Low platelet count is a marker of portal hypertension but is
not routinely included in the standard preoperative evaluation
of patients with hepatocellular carcinoma (HCC) because it
pertains to liver function (Child/model for end-stage liver dis-
ease [MELD] score) and tumor burden (Milan criteria). Ben-
nett and Blumgart hypothesized that low platelet count less
than 100 · 103/mm3, was independently associated with in-
creased major complications, postoperative liver insufﬁciency,
and mortality after resection of HCC, even when accounting
for standard criteria, such as Child/MELD score and tumor
extent, used to select patients for resection (13).
Our results revealed that the platelet count was not an inde-
pendent predictive factor for the development of liver decom-
pensation after RFA of HCC, likely because RFA spares
much more non tumoral liver than resection. We found also
that patients with thrombocytopenia and a prothrombin
time 6 63% had a signiﬁcant higher risk of occurrence of liver
decompensation following RFA therapy of HCC. Prothrom-
bin time is in fact a well known marker of liver function and
on this account it is commonly used in the main prognostic
scores of chronic liver disease as the Child-Pugh or Model of
End-Stage Liver Disease (MELD) scores (14). In a prospective
analysis of risk factors of morbidity and mortality following
the surgical resection for Hepatocellular carcinoma, Kim and
Colleagues reported that an increased prothrombin time was
one of the most sensitive indicators of peri-operative mortality
independent of the Child-Pugh score and hypothesized that
intraoperative transfusion, which is mainly related to intraop-
erative bleeding, should be reduced if possible to decrease mor-
bidity (15).
Some limitations of this study must be addressed. First, this
was a retrospective study of a small sample of subjects. Be-
cause thrombocytopenia was considered a relative contraindi-
cation for performing RFA in our institution, patients with
thrombocytopenia 60 · 103/mm3 were not commonly referredto planning sonography of RFA. Second, we could not evalu-
ate objectively the response of patients to medications admin-
istered to control thrombocytopenia before RFA. Finally,
accurate assessment of the safe account of platelets and the
optimal time to perform RFA after thrombocytopenia control
should be investigated with further prospective studies.
In summary, for patients with cirrhosis and HCC treated by
RFA, mild thrombocytopenia above 37 · 103/mm3 platelets
per liter is not an independent risk factor of bleeding or liver
decompensation. However when thrombocytopenia is associ-
ated with a prothrombin time 6 63, % the risk of liver decom-
pensation after RFA signiﬁcantly increases. Therefore in such
conditions, caution is required in indication of RFA especially
if large volume of tissue ablation is planned and in the perspec-
tive of the future improvements of the destructive capacities of
radiofrequency devices.
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